HFA Premium Access

Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction

Congress Presentation

About the speaker

Miss Martina Amiguet Comins

General University Hospital of Castellon, Castellon de la Plana (Spain)
0 follower

5 more presentations in this session

Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series

Speaker: Doctor J. Brito (Lisbon, PT)


Trace element equilibrium in acute heart failure and the effect of empagliflozin

Speaker: Assistant Professor N. Bomer (Groningen, NL)


Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.

Speaker: Doctor R. Rascon Sabido (Veracruz, MX)


Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction

Speaker: Doctor J. Youn (Seoul, KR)


REALM-DCM: a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 (PF-07265803) in patients with symptomatic LMNA-related dilated cardiomyopathy

Speaker: Doctor R. Barriales-Villa (Coruna, A, ES)


Access the full session

Chronic heart failure - pharmacotherapy 5

Speakers: Miss M. Amiguet Comins, Doctor J. Brito, Assistant Professor N. Bomer, Doctor R. Rascon Sabido, Doctor J. Youn...

About the event


Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

ESC 365 is supported by